Allos Therapeutics ( ALTH) Drug/indication: Pralatrexate for peripheral T-cell lymphoma FDA decision date: Sept. 24 Allos expects the FDA to convene an advisory panel meeting to review pralatrexate, although a meeting has not been formally announced. The scheduling of the advisory meeting may delay the FDA's approval decision. Amgen ( AMGN) Drug/indication: Denosumab for osteoporosis FDA advisory panel date: Aug. 13 FDA decision date: Oct. 19 Denosumab is the most important drug in the company's late-stage pipeline. Approval for osteoporosis, and later for certain cancer indications, could re-invigorate earnings growth after a couple of flat years. Denosumab's safety profile will be the focus of the Aug. 13 advisory panel meeting. Acorda Therapeutics ( ACOR) Drug/indication: Fampridine for multiple sclerosis FDA decision date: Oct. 22 Fampridine improves nerve function and is being developed to improve the walking abilities of patients with multiple sclerosis. GTx ( GTXI) Drug/indication: Acapodene for prostate cancer FDA decision date: Oct. 30 Acapodene is designed to reduce bone fractures in prostate cancer patients being treated with androgen deprivation therapy. Transcept Pharmaceuticals ( TSPT) Drug/indication: Intermezzo for insomnia FDA decision date: Oct. 30 Intermezzo is a dissolvable, low-dose form of the sleep aid Ambien which will be marketed for people who awake in the middle of the night but can't fall back to sleep. Cadence Pharmaceuticals ( CADX) Drug/indication: Acetevance for acute pain/fever FDA decision date: Nov. 13 Acetevance is an injectable form of the painkiller acetaminophen for use in hospitals. Somaxon Pharmaceuticals ( SOMX) Drug/indication: Silenor for insomnia FDA decision date: Dec. 4 The FDA refused to approve Silenor last February, requesting additional clinical information from Somaxon. The company resubmitted Silenor in June.